^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Chronic Lymphocytic Leukemia)
New
Excerpt:
Venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Venetoclax with decitabine or azacitidine in previously untreated TP53mut acute myeloid leukemia.

Published date:
05/25/2023
Excerpt:
We retrospectively analyzed 35 patients with del17p or TP53mut AML treated with venetoclax + HMA or HMA alone….The composite complete remission (CCR) rate significantly favored the venetoclax arm at 40.0% (95% CI, 21.9 - 61.3), compared to 0% (95% CI, 0 - 27.8) in the monotherapy arm (p = 0.029). Furthermore, the median overall survival significantly favored the venetoclax cohort at 6.0 months compared to 3.4 months in the HMA cohort (p = 0.026)....The addition of venetoclax offers significantly superior response and survival compared to HMA monotherapy in patients with del17p or TP53mut AML.
Secondary therapy:
azacitidine; decitabine
DOI:
10.1200/JCO.2023.41.16_suppl.e19051